IRD
Ticker
Opus Genetics, Inc.
IRD · Healthcare · Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patient…Opus Genetics, Inc. (IRD), in the Healthcare sector, has 5 disclosed filings on Paydirt over the trailing twelve months from 4 corporate insiders: 1 purchase and 4 sales. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Sep 3 and filed Sep 8. The most active filer was Foundation Fighting Blindness Retinal Degeneration Fund with 2 filings.
Add to watchlistFilings, ttm
5
1 buy · 4 sells
Traders, ttm
4
4 insiders
Volume, ttmiDollar value disclosed in the window
$16.6M
estimated for Congress, as filed for insiders
Median delay
2d
execution to disclosure
Last traded
Sep 3
Filed Sep 8
ADViAverage daily dollar volume
$4.8M
market data
Share price · 12M
$6.04 (+253.2%)
Adjusted for splits and dividends.
Volume by month
Buys $324K
Sells $16.2M
Estimated for Congress, as filed for insiders · by filing month · past 24 months
Who filed
FF
Foundation Fighting Blindness Retinal Degeneration Fund
Director
2 filings
RG
Robert E. Gagnon
Chief Financial Officer
1 filing
CG
Cam Gallagher
Director
1 filing
GM
George Magrath
Chief Executive Officer
1 filing
Recent filings
Robert E. GagnonSALE
Chief Financial Officer
$127K28,000 sh × $4.54
Exec Sep 3
Filed Sep 8 · 4:05 PM ET Foundation Fighting Blindness Retinal Degeneration FundSALE Director $7.4M
1,700,000 sh × $4.35
Exec May 18
Filed May 20 · 5:30 PM ET George MagrathSALE Chief Executive Officer $127K
24,438 sh × $5.21
Exec Mar 16
Filed Mar 18 · 5:30 PM ET Cam GallagherPURCHASE Director $324K
164,000 sh across 2 lots
Exec Dec 29 2025
Filed Dec 31 2025 · 4:33 PM ET Foundation Fighting Blindness Retinal Degeneration FundSALE Director $8.6M
4,000,000 sh × $2.15
Exec Dec 9 2025
Filed Dec 11 2025 · 5:30 PM ET